Evidence map›Paper›PMID 40739266›Full record

ArticleEuropean journal of medical research2025

Competing risk analysis of dexmedetomidine use and postoperative outcomes in non-traumatic subarachnoid hemorrhage patients.

Tian-Hua Lin, Zong-Jie Wang, Yun-Yun Tu, Mu-Hua Dong, Ting Qiu, Wen-Jie Lan, Ying Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tian-Hua Lin *Department of Anesthesiology, Longyan First Affiliated Hospital of Fujian Medical University, No.105, Jiuyi North Road, Zhongcheng, Longyan, 364000, Fujian, China.
Zong-Jie Wang *Department of Anesthesiology, Longyan First Affiliated Hospital of Fujian Medical University, No.105, Jiuyi North Road, Zhongcheng, Longyan, 364000, Fujian, China.
Yun-Yun TuDepartment of Anesthesiology, Longyan First Affiliated Hospital of Fujian Medical University, No.105, Jiuyi North Road, Zhongcheng, Longyan, 364000, Fujian, China.
Mu-Hua DongDepartment of Outpatient, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, 364000, Fujian, China.
Ting QiuDepartment of Anesthesiology, Longyan First Affiliated Hospital of Fujian Medical University, No.105, Jiuyi North Road, Zhongcheng, Longyan, 364000, Fujian, China.
Wen-Jie LanDepartment of Anesthesiology, Longyan First Affiliated Hospital of Fujian Medical University, No.105, Jiuyi North Road, Zhongcheng, Longyan, 364000, Fujian, China.
Ying ChenDepartment of Anesthesiology, Longyan First Affiliated Hospital of Fujian Medical University, No.105, Jiuyi North Road, Zhongcheng, Longyan, 364000, Fujian, China. lycheny2025@163.com.

Funding

Fujian Province Natural Science Foundation 2021J011438Longyan City Science and Technology Plan Project 2022LYF17099
6 · The paper itself

Abstract

backgroundDexmedetomidine is widely used in critically ill patients, but its effects on postoperative outcomes in non-traumatic subarachnoid hemorrhage (SAH) patients remain unclear. This study focuses on exploring the impact of dexmedetomidine on postoperative respiratory failure (RF) and in-hospital mortality.

methodsThe data were downloaded from the Medical Information Mart for Intensive Care (MIMIC-IV) database, including 817 non-traumatic SAH patients. Propensity score matching (PSM) was performed. Multivariable logistic regression, sensitivity, interaction, and subgroup analyses were used to examine the association between dexmedetomidine use and RF or in-hospital mortality. A competing risk model was employed, with RF defined as the event of interest and in-hospital mortality as the competing event, to evaluate the survival probabilities for both outcomes.

resultsDexmedetomidine use was a risk factor for RF but a protective factor for in-hospital mortality both pre-/post-PSM (p < 0.05). The protective effect of dexmedetomidine on mortality was more pronounced in younger patients (≤ 62 years) and those without cerebrovascular disease. Competing risk analysis showed that even after adjusting for confounders, dexmedetomidine remained a significant protective factor for in-hospital mortality, but did not affect the incidence of RF.

conclusionsDexmedetomidine use in non-traumatic SAH patients significantly reduces in-hospital mortality but does not affect the incidence of postoperative RF. These findings highlight the importance of considering competing risks when evaluating the effects of dexmedetomidine on postoperative outcomes.

Indexed as

DexmedetomidinePostoperative ComplicationsRespiratory InsufficiencySubarachnoid HemorrhageAdultAgedFemaleHospital MortalityHumansHypnotics and SedativesMaleMiddle AgedRisk AssessmentRisk FactorsDexmedetomidineHypnotics and SedativesCompeting risk analysisDexmedetomidineIn-hospital mortalityNon-traumatic subarachnoid hemorrhageRespiratory failure

Identifiers

PMID40739266
PMCPMC12309114

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.